Comparing SG&A Expenses: Halozyme Therapeutics, Inc. vs Viking Therapeutics, Inc. Trends and Insights

SG&A Expenses: A Tale of Two Biotech Companies

In the competitive world of biotechnology, managing expenses is crucial for success. This chart highlights the Selling, General, and Administrative (SG&A) expenses of Halozyme Therapeutics, Inc. and Viking Therapeutics, Inc. from 2014 to 2023. Over this period, Halozyme's SG&A expenses surged by over 300%, peaking in 2023, while Viking's expenses increased by nearly 2,900%, reflecting its growth trajectory. Notably, Halozyme's expenses consistently outpaced Viking's, indicating a more aggressive investment in administrative and sales functions. The year 2022 marked a significant leap for both companies, with Halozyme's expenses nearly doubling from the previous year, and Viking's expenses more than tripling by 2023. These trends underscore the dynamic nature of the biotech industry, where strategic financial management can be a key differentiator in achieving market leadership.

Key Insights

• Halozyme's SG&A expenses grew steadily, reflecting strategic investments.
• Viking's expenses showed rapid growth, indicating expansion efforts.